Division of Bone Diseases [WHO Collaborating Center for Osteoporosis Prevention], Department of Rehabilitation and Geriatrics and Faculty of Medicine, University Hospital of Geneva, Geneva 14, Switzerland.
Bone. 2010 May;46(5):1436-41. doi: 10.1016/j.bone.2010.01.379. Epub 2010 Jan 29.
Endosseous implantation is a frequent procedure in orthopaedics and dentistry, particularly in the aging population. The incidence of implant failure, however, is high in situations where the bone at the site of implantation is not of optimal quality and quantity. Alterations of bone turnover and changes in intrinsic bone tissue quality have potentially negative effects on optimal osseointegration. Strontium ranelate, which acts on both resorption and formation, and improves biomaterial properties, is hypothesized to improve osseointegration and this hypothesis was tested here.
Titanium implants were inserted into the proximal tibias of thirty 6-month-old Sprague-Dawley female rats. During the 8 weeks following implantation, animals received orally strontium ranelate (SrRan) 5 days a week (625 mg/kg/day) or saline vehicle. Pull-out strength, microCT and nanoindentation were assessed on the implanted tibias.
SrRan significantly increased pull-out strength compared to controls (+34%). This was associated with a significant improvement of bone microarchitecture around the implant (BV/TV+36%; Tb.Th+13%; Conn.D+23%) with a more plate-shape structure and an increase in bone-to-implant contact (+19%). Finally, strontium ranelate had a significant beneficial effect on parameters of bone biomaterial properties at both cortical (modulus+11.6%; hardness+13%) and trabecular areas (modulus+7%; hardness+16.5%).
SrRan is an antiosteoporotic agent that increased mechanical fixation of the implant. The improvement of pull-out strength was associated with an improvement of implant osseointegration with both a positive effect on bone microarchitecture and on bone biomaterial properties in the vicinity of the implant. These current results may support potential benefits of strontium ranelate in orthopaedic and dental surgery to enhance osseointegration.
在矫形和牙科领域，骨内植入是一种常见的手术，特别是在老年人群中。然而，在植入部位的骨质量和数量不理想的情况下，植入物的失败率很高。骨转换的改变和内在骨组织质量的变化可能对最佳骨整合产生负面影响。雷奈酸锶作用于吸收和形成，并改善生物材料性能，据推测可以改善骨整合，本研究对此进行了检验。
将钛植入物插入 30 只 6 月龄 Sprague-Dawley 雌性大鼠的胫骨近端。在植入后的 8 周内，动物每周接受 5 天雷奈酸锶（SrRan）口服治疗（625mg/kg/天）或生理盐水载体。对植入胫骨进行拔出强度、微 CT 和纳米压痕测试。
与对照组相比，SrRan 显著增加了拔出强度（+34%）。这与植入物周围骨微结构的显著改善有关（BV/TV+36%；Tb.Th+13%；Conn.D+23%），具有更板状结构和骨-植入物接触增加（+19%）。最后，雷奈酸锶对皮质（模量+11.6%；硬度+13%）和小梁区（模量+7%；硬度+16.5%）骨生物材料性能参数有显著的有益影响。
SrRan 是一种抗骨质疏松药物，可增加植入物的机械固定。拔出强度的提高与植入物骨整合的改善有关，对骨微结构和植入物附近的骨生物材料性能均有积极影响。这些当前结果可能支持雷奈酸锶在矫形和牙科手术中的潜在益处，以增强骨整合。
